

8-hydroxyquinoline in an amount of at least five percent of the composition
by weight;

an escharotic chelatable metal agent bonded to said 8-hydroxyquinoline
including a metal having an oxidation state of +2 present in a concentration of at
least five percent by weight of the composition and less than an amount that
produces an eschar in healthy mammalian tissues; and

a carrier,

[wherein said 8-hydroxyquinoline and said chelatable metal agent are
present in effective amounts for treating mammalian lesions selected from the
group consisting of cancerous lesions, precancerous lesions, and warts]

B'cont
the composition having a capacity for treating at least one type of lesion
selected from the group consisting of venereal warts, male veruoca warts,
lesions produced by the human papilloma virus, basal cell carcinoma, solar
keratosis, Kaposi's sarcoma, eye cancer, sarcoids, sarcoma, malignant
melanoma, rectal adenoma, histocytoma, sebaceous adenoma, lung cancer,
breast cancer, and colon cancer.

2. (Amended) The composition as set forth in claim 1 [wherein said
effective amounts include] including a ratio of 8-hydroxyquinoline to said
chelatable metal agent ranging from 1:1 to 1:3 by weight.

3. (Amended) The composition as set forth in claim [2]1 wherein said
ratio is about 1:2.

4. (Amended) The composition as set forth in claim [2]1 wherein said metal agent comprises zinc [effective amounts are therapeutically effective without producing an eschar].

5. (Amended) The composition as set forth in claim [4]1 wherein said [effective amounts include] escharotic chelatable metal agent comprises zinc chloride in an amount up to forty percent by weight [as said chelatable metal agent in an amount ranging from five to twenty percent] of said composition by weight].

B' cont
6. (Amended) The composition as set forth in claim 1 wherein said [effective amounts include] escharotic chelatable metal agent comprises zinc chloride [as said chelatable metal agent] in an amount ranging [from five] up to twenty percent.

7. (Amended) The composition as set forth in claim 1 in combination with necrotic tissue from lesions of said group produced by the action of said composition upon said necrotic tissue [wherein said effective amounts are therapeutically effective without producing an eshcar]

8. Cancelled.

9. Cancelled.

10. Cancelled.

11. Cancelled.

12. Cancelled.

13. Cancelled.

14. The composition as set forth in claim 1 wherein said carrier is a gel base.

15. The composition as set forth in claim 15 wherein said gel base is a polyoxyalkylene ether derivative of propylene glycol.

16. The composition as set forth in claim 1 wherein said carrier contains a penetrant.

17. The composition as set forth in claim 1 wherein said penetrant is lecithin.

18. The composition as set forth in claim 1 wherein said penetrant is dimethyl sulfoxide.

19. The composition as set forth in claim 1 wherein said carrier contains an antioxidant.

20. The composition as set forth in claim 19 wherein said antioxidant is selected from the group consisting of nordihydroguaiaretic acid, nordihydroguaiaretic acid derivatives, and functional homologues of nordihydroguaiaretic acid.

21. The composition as set forth in claim 19 wherein said antioxidant is selected from a group consisting of ascorbic acid, ascorbic acid derivatives, and functional homologues of ascorbic acid.

B²
22. The composition as set forth in claim 1 including quercetin as a source of the 8-hydroxyquinoline [wherein said 8-hydroxyquinoline is derived from quercetin in said composition].